Previous 10 | Next 10 |
Briggs & Stratton (NYSE: BGG ) -47% . on Q4 earnings & dividend cut. More news on: Briggs & Stratton Corporation, Just Energy Group Inc., Akari Therapeutics, Plc, Stocks on the move, Read more ...
It’s not easy to get approval from the FDA. There are steps to follow, standards to meet. Sometimes, companies fail. But Akari Therapeutics (NASDAQ:AKTX) is not one of them, receiving Fast Track approval from the federal agency this week. On the news, AKTX stock jumped, currently u...
Gainers: Infrastructure and Energy Alternatives (NASDAQ: IEA ) +61% . Novavax (NASDAQ: NVAX ) +40% . Akari Therapeutics (NASDAQ: AKTX ) +31% . Xunlei Limited (NASDAQ: XNET ) +30% . Presidio (NASDAQ: PSDO ) +21% . Purple Innovation (NASDAQ: PRPL ) +22% . InMode (NASDAQ: INMD ) ...
Akari Therapeutics (NASDAQ: AKTX ) +57% as nomacopan Fast Track'd for HSCT-TMA. More news on: Akari Therapeutics, Plc, InMode Ltd., Presidio, Inc., Stocks on the move, Read more ...
Thinly traded nano cap Akari Therapeutics (NASDAQ: AKTX ) is up 62% premarket on robust volume in reaction to the FDA's granting of Fast Track status for Coversin (nomacopan) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA...
Fast Track designation by the U.S. Food and Drug Administration (FDA) facilitates the development and expedites the review of new medicines like nomacopan that treat serious unmet medical needs and in Akari’s case, pediatric patients with HSCT-TMA. The Fast Track designat...
New data from bullous pemphigoid (BP) patients and pemphigoid disease (PD) models generated by Dr. Christian Sadik’s group at University of Lubeck, Germany published in the August 2019 edition of JCI Insight (see link to article HERE ) Preclinical PD model shows maxima...
NEW YORK and LONDON, July 31, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced ...
Akari Therapeutics ( AKTX -5.3% ) has priced its registered direct offering of ~2,368,421 registered ADS at a purchase price of $1.9/ADS, for gross proceeds of $4.5M . More news on: Akari Therapeutics, Plc, Read more ...
NEW YORK and LONDON, June 28, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced ...
News, Short Squeeze, Breakout and More Instantly...
Akari Therapeutics Plc Company Name:
AKTX Stock Symbol:
NASDAQ Market:
PRA Group Inc. (PRAA) is expected to report $-0.15 for Q1 2024 Bowman Consulting Group Ltd. (BWMN) is expected to report $-0.04 for Q1 2024 Noble Corporation plc A (NE) is expected to report $0.56 for Q1 2024 Velo3D Inc. (VLD) is expected to report for Q3 2024 Axon Enterprise Inc....
BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing advanced therapies...
Prioritization of Peak's ADC cancer therapeutic platform technology and Akari's PAS-nomacopan for Geographic Atrophy, a disabling ophth...